| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
Purity: N/A
| Targets |
Collagens do not have a pharmacological target in the traditional sense. They are structural proteins that serve as the primary components of the extracellular matrix in various tissues. Their biological function is to provide structural support, tensile strength, and a scaffold for cell attachment and tissue organization. In biomedical applications, collagens are used as biomaterials for wound healing, tissue engineering, and drug delivery.
|
|---|---|
| ln Vitro |
In vitro, collagens are used as substrates for cell culture, promoting cell adhesion and growth. They are also used in various assays to study cell-matrix interactions. Type II collagen, for example, is used in research related to osteoarthritis. Collagen-based biomaterials are also studied for their biocompatibility and ability to support tissue regeneration.
|
| ln Vivo |
In vivo, collagens are used in various biomedical applications. Collagen-based materials are used for wound healing, as hemostatic agents, and as scaffolds for tissue engineering. Collagen injections are used in cosmetic procedures for soft tissue augmentation. Type II collagen is being studied for its potential in treating osteoarthritis.
|
| Enzyme Assay |
A cell-free assay for collagens is not applicable as they are structural proteins, not enzyme inhibitors. Their properties are characterized by physical and biochemical methods, such as assessing their tensile strength, thermal stability, and ability to form fibrils. Their biocompatibility is typically assessed in cell culture or in vivo.
|
| Cell Assay |
Cellular experiments with collagens typically involve studying cell-matrix interactions. Cells are cultured on collagen-coated surfaces, and their adhesion, proliferation, and differentiation are assessed. Collagen gels are used as three-dimensional culture models to study cell behavior in a more physiologically relevant environment.
|
| Animal Protocol |
In vivo animal experiments for collagens are typically conducted to evaluate their biocompatibility and efficacy as biomaterials. Collagen-based scaffolds or implants are placed in animal models to study tissue regeneration, wound healing, or the treatment of conditions like osteoarthritis.
|
| ADME/Pharmacokinetics |
Collagens are large, structural proteins with high molecular weights. Their pharmacokinetic properties are not relevant in the context of small-molecule drugs. When used as biomaterials, they are designed to be biocompatible and biodegradable. The specific properties depend on the source and processing of the collagen.
|
| Toxicity/Toxicokinetics |
Collagens are generally considered biocompatible and have low toxicity. However, the safety profile depends on the source and processing of the material. Potential risks include immunogenicity and transmission of infectious agents. Collagens used in medical devices are subject to rigorous quality control and safety testing.
|
| References | |
| Additional Infomation |
A polypeptide that makes up about one-third of the total protein in mammals. It is a major component of skin, connective tissue, as well as bones and teeth.
See also: Collagen (note moved to). Collagens (CAS: 9007-34-5) are the most abundant proteins in mammals and are the primary components of the extracellular matrix. They have numerous applications in the food, cosmetic, pharmaceutical, and biomedical industries. Type II collagen is studied for its potential in treating osteoarthritis. Collagens are not drugs in the traditional sense but are used as biomaterials and therapeutic proteins. |
| Molecular Weight |
0
|
|---|---|
| Exact Mass |
300.179
|
| CAS # |
9007-34-5
|
| PubChem CID |
74077706
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
558.2±60.0 °C at 760 mmHg
|
| Flash Point |
291.4±32.9 °C
|
| Vapour Pressure |
0.0±3.4 mmHg at 25°C
|
| Index of Refraction |
1.604
|
| Source |
Bovine cartilage
|
| LogP |
-0.82
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
34
|
| Complexity |
653
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
YBUAWZQWIXYUFU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C25H48N4O5/c1-9-10-11-26-23(32)17(6)14-22(31)20(12-15(2)3)29-24(33)18(7)27-25(34)21(13-16(4)5)28-19(8)30/h15-18,20-22,31H,9-14H2,1-8H3,(H,26,32)(H,27,34)(H,28,30)(H,29,33)
|
| Chemical Name |
5-[2-[(2-acetamido-4-methylpentanoyl)amino]propanoylamino]-N-butyl-4-hydroxy-2,7-dimethyloctanamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~50 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA